Mutant capable of enhancing FcRn receptor binding

• Main Authors: CAO CHUNLAI, LI-ZHANG WANJIN, LIANG XIONGJI, FAN CHANG, ZHANG PENG, LIANG ZHIYU, YANG XIAOCHUN, HE XIUYI, LIU HEDONG, LI SUWEN, HUANG GUOZHOU, ZHOU CUI
• Format: Patent
• Language: Chinese; English
• Published: 06.01.2023
• Subjects: CHEMISTRY; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES

The invention relates to the field of biological medicines, and in particular provides a mutant of a human IgG Fc fragment capable of enhancing FcRn receptor binding, and the mutant comprises M252, Q311, M428, N434, or Y436, or mutations of two or more mutation sites in the M252, Q311, M428, N434, or Y436. The Fc mutant provided by the invention has the advantages that the affinity of an FcRn receptor is enhanced, the immunogenicity is relatively low, the safety risk is not increased, and the potential clinical application value is realized. 本发明涉及生物医药领域，具体提供一种具有增强FcRn受体结合的人IgG Fc片段的突变子，其中所述突变子包含M252、Q311、M428、N434、或Y436，或它们中的两个或两个以上突变位点的突变。本发明提供的Fc突变子具有增强FcRn受体亲和力，免疫原性较低，不增加安全性风险，有潜在的临床应用价值。